Ultima-DES (1-3), 1 mg

Ultima-DES (1-3) 1 mg contains DES (1-3) IGF-1, a modified form of insulin-like growth factor-1 associated with muscle growth, protein synthesis, nutrient utilization, and recovery. Its shorter-acting profile compared with IGF-1 LR3 makes it particularly relevant to applications focused on localized growth-factor activity and post-training recovery.

How it works

DES (1-3) IGF-1 interacts with IGF-1 receptors on cells, activating signaling pathways involved in protein synthesis, cellular growth, glucose utilization, and tissue development.

The modified structure has reduced binding to certain IGF-binding proteins, allowing greater receptor interaction and a shorter, more localized activity profile. This makes IGF-1 DES particularly associated with direct growth-factor signaling around muscle tissue.

Proper Use and Dosage

The listed presentation contains 1 mg (1,000 mcg) of IGF-1 DES.

For quantity reference:

• 20 mcg = 50 administrations
• 25 mcg = 40 administrations
• 50 mcg = 20 administrations
• 75 mcg = approximately 13 administrations
• 100 mcg = 10 administrations
• 150 mcg = approximately 6–7 administrations
• 200 mcg = 5 administrations
• 250 mcg = 4 administrations
• 500 mcg = 2 administrations
• 1 mg = 1 full vial

Because IGF-1 DES is a potent growth-factor peptide, administration amount and frequency should be approached carefully and based on the intended application.

Benefits

Ultima-DES (1-3) is particularly suited to applications involving muscle development, recovery, nutrient utilization, and growth-factor signaling.

Key benefits and areas of interest include:

• Supports IGF-1 receptor signaling
• Promotes muscle protein synthesis
• Supports muscle-cell growth
• Enhances nutrient utilization
• Supports post-training recovery
• Promotes cellular growth pathways
• Supports tissue-development processes
• May complement hypertrophy-focused training
• Shorter-acting IGF-1 profile
• Convenient 1 mg presentation

Its distinctive receptor activity and shorter duration make IGF-1 DES particularly appealing for applications focused on direct growth-factor signaling and muscle-development pathways.

Side Effects

Possible effects may include headache, dizziness, fatigue, nausea, injection-site irritation, water retention, and changes in blood-glucose levels. Excessive IGF-1 activity may also contribute to hypoglycemia, swelling, joint discomfort, or tingling sensations.